Physician profile
Rose Khavari
NPI 1295066397
$7,216.36
in general payments reported to CMS, 2019-2025
29 companies · $988 in 2025
The $988 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $1,060 · 2021: $1,023 · 2022: $1,185 · 2023: $829 · 2024: $883 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,032.82 | 2019-2025 | Solyx Sis System, Axonics, Ams 800 Artificial Urinary Sphincter |
| Medtronic, INC. | $1,185.38 | 2022-2025 | Interstim |
| Allergan, INC. | $856.97 | 2019-2022 | |
| Abbvie INC. | $663.53 | 2022-2025 | |
| Astellas Pharma US INC | $250.84 | 2021-2022 | |
| Medtronic USA, INC. | $222.55 | 2019-2020 | |
| Axonics, INC. | $208.96 | 2020-2023 | Axonics |
| Biotissue Holdings INC. | $133.34 | 2022-2024 | |
| 180 Medical, INC. | $94.41 | 2019-2023 | |
| Convatec INC. | $74.02 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $56.18 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $45.50 | 2024 | Rivfloza |
| Alafair Biosciences, INC. | $43.46 | 2022 | |
| Myovant Sciences INC. | $40.86 | 2021 | |
| Urovant Sciences INC | $33.96 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $26.22 | 2022 | |
| Urogen Pharma, INC. | $25.11 | 2023 | Jelmyto |
| Laborie Medical Technologies Corp. | $24.97 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Endo Pharmaceuticals INC. | $24.35 | 2020-2021 | |
| Avation Medical, INC. | $23.67 | 2024 | Vivally |
| Ambu INC. | $22.02 | 2025 | |
| Ethicon US, LLC | $20.64 | 2021 | |
| Dentsply Ih INC. | $19.62 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.54 | 2025 | Exparel |
| Pfizer INC. | $17.89 | 2019 | |
| Endo USA, INC. | $17.69 | 2024 | Aveed, Xiaflex |
| Myriad Genetic Laboratories, INC. | $17.13 | 2020 | |
| Acerus Pharmaceuticals Corporation | $15.73 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Khavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.